Reuters logo
BRIEF-Prothena reports results from phase 1b multiple ascending dose study of PRX003 in patients with Psoriasis
September 28, 2017 / 8:14 PM / 25 days ago

BRIEF-Prothena reports results from phase 1b multiple ascending dose study of PRX003 in patients with Psoriasis

Sept 28 (Reuters) - Prothena Corporation Plc

* Prothena reports results from phase 1b multiple ascending dose study of PRX003 in patients with psoriasis

* Prothena Corporation Plc - ‍prx003 was shown to be generally safe and well tolerated up to and including highest dose level tested at 30 mg/kg​

* Prothena Corporation - ‍there were no serious adverse events in PRX003-treated patients and two patients discontinued study drug due to adverse events​

* Prothena Corporation- clinical results in study did not meet pre-specified criteria evidence required to advance PRX003 to mid-stage clinical development Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below